protein
| binds specifically to PDGFRA and has a tyrosine-protein kinase activity |
|
interacting with NRP1 (influences ligand-induced PDGFRB homodimer signalling) |
|
important interactive relationship between SLC6A4 and the PDGFRB in the production of pulmonary artery smooth muscle cell proliferation triggered by PDGF that may be important in pulmonary hypertension (PH) |
|
LRP6 forms a complex with PDGFRB and promotes its degradation |
|
SH2B3 is a negative regulator of PDGFR signaling |
|
in aortic smooth muscle cells, TGM2 specifically amplifies the activation of PDGFRB and its multiple downstream signaling targets in response to PDGF-BB |
|
ETV6-PDGFRB antagonizes the effects of ETV6 and IRF8 on PTPN13 transcription |
|
PDGFRB/MAPK1 signalling pathway triggered by FGF2 plays an important role in the proliferation and migration of endothelial progenitor cells |
|
involved in angiogenesis and in the regulation of inorganic phosphate (Pi) transport in vascular smooth |
|
muscle cells via SLC20A1 |
|
PDGFRB expression was upregulated by NOTCH3 ligand induction or by activated forms of the NOTCH3 receptor |
|
affects the intracellular sorting of activated PDGFRB and the migration, proliferation and tumorigenicity of cells stimulated by PDGF |
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
|  
| gain of function
|
in clear cell renal carcinoma with favourable outcome | tumoral
| fusion
| translocation
|  
| protein chimeric
|
t(5;12)(q33;p13) in myelodysplasia, myeloproliferative disorders (MPS), chronic myelocytic leukemia (CMLL), with fusion 5' - ETV66 - PDGFRB - 3' | constitutional
| germinal mutation
|  
|  
|  
|
gain of function mutation in the activation loop deregulates its kinase activity | tumoral
| fusion
| translocation
|  
|  
|
somatic traslocations in various hematological disorders resulting in PDGFRB/D10S170 fusion gene, PDGFRB/RABPT5 fusion gene, PDGFRB/HIP1 fusion gene and other partners genes | tumoral
| fusion
|  
|  
|  
|
with MYO18A in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2) | tumoral
| fusion
|  
|  
|  
|
to SPTBN1 in imatinib-responsive atypical myeloproliferative disorders | constitutional
| somatic mutation
|  
|  
|  
|
in intracerebral fusiform aneurysms | |